| Literature DB >> 24034465 |
Kenneth Day, Lindsay L Waite, Anna Thalacker-Mercer, Andrew West, Marcas M Bamman, James D Brooks, Richard M Myers, Devin Absher.
Abstract
BACKGROUND: DNA methylation is an epigenetic modification that changes with age in human tissues, although the mechanisms and specificity of this process are still poorly understood. We compared CpG methylation changes with age across 283 human blood, brain, kidney, and skeletal muscle samples using methylation arrays to identify tissue-specific age effects.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24034465 PMCID: PMC4053985 DOI: 10.1186/gb-2013-14-9-r102
Source DB: PubMed Journal: Genome Biol ISSN: 1474-7596 Impact factor: 13.583
Figure 1Linear regression results showed an association between DNA methylation and age across four human tissues. (A) Uniform quantile-quantile (Q-Q) plots of -log P-values from linear regression tests for associations between β-score and age within blood, brain, kidney, and skeletal muscle tissue samples. (B) Scatterplots for the top five strongest associations between β-score and age across each of the four tissues. Illumina CpG ID, P-value, and R-squared results are depicted above each scatterplot.
Figure 2Bar graphs displaying the percentages of ageCGs classified by CpG context and positive or negative association with age across four human tissues. (A) Percentage of total ageCGs that exhibited a positive or negative association with age in each tissue. (B,C) Percentage of positively associated (B) and negatively associated ageCGs (C) positioned within CpG islands, shores, or other. (D-F) Percentages of positively or negatively associated ageCGs each classified within CpG islands (D), CpG shores (E), or CpG other contexts (F). P-values are below bar graphs that resulted from Pearson’s Chi-squared tests between number of positive or negative associations across tissues in each respective CpG context.
CpG context profiles of ageCGs and non-ageCGs across tissues
| | | | |
| | 533 (57.7%) | 8,106 (45.2%) | |
| | 217 (23.5%) | 5,915 (33.0%) | 2.48 × 10-13 |
| | 174 (18.8%) | 3,923 (21.9%) | |
| | | | |
| | 646 (54.1%) | 7,486 (49.4%) | |
| | 351 (29.4%) | 5,132 (33.9%) | 3.16 × 10-3 |
| | 198 (16.6%) | 2,532 (16.7%) | |
| | | | |
| | 987 (36.8%)e | 6,005 (46.2%) | |
| | 859 (32.1%) | 4,086 (31.5%) | <2.2 × 10-16 |
| | 833 (31.1%) | 2,898 (22.3%) | |
| | | | |
| | 476 (48.6%) | 5,978 (41.6%) | |
| | 242 (24.7%) | 5,038 (35.1%) | 3.14 × 10-10 |
| | 262 (26.7%) | 3,353 (23.3%) |
aPercentage of total CpGs for each tissue indicated in parentheses.
bAge-associated CpGs (q < 0.05 with linear regression model).
cNon-age-associated CpGs (q > 0.5 with linear regression model).
dResulting P-values from Pearson’s Chi-squared tests (3x3 contingency tables containing ageCGs and non-ageCGs).
eAgeCGs from kidney tissue are less frequently found in islands compared to other tissues.
Figure 3Boxplots of slope magnitude grouped according to positive (+) or negative (-) ageCGs and CpG context across four tissues. Vertical red and green lines mark the smallest and largest median slope magnitude, respectively, across all four tissues. A significant three-way interaction between CpG context, tissue type, and positive or negative slope trend was found among slope magnitude values (ANOVA on Box-Cox power transformed slope values, P = 5.4 × 10-5).
Summary of Gene Ontology terms associated with positive and negative ageCGs affiliated with genes across tissues
| | | | | | |
| GO:0030054 - cell junction | Blood | 42 | 5.2 × 10-10 | 7.0 × 10-7 | 3.1 |
| GO:0048754 - branching morphogenesis of a tube | Brain | 18 | 1.6 × 10-7 | 3.0 × 10-4 | 5.0 |
| GO:0048878 - chemical homeostasis | Kidney | 87 | 4.9 × 10-15 | 9.0 × 10-12 | 2.6 |
| GO:0003713 - transcription coactivator activity | Muscle | 15 | 6.6 × 10-7 | 1.0 × 10-3 | 5.6 |
| | | | | | |
| GO:0000902 - cell morphogenesis | Blood | 37 | 2.3 × 10-14 | 4.0 × 10-11 | 4.9 |
| GO:0003002 - regionalization | Brain | 41 | 5.3 × 10-15 | 9.6 × 10-12 | 4.6 |
| GO:0000902 - cell morphogenesis | Kidney | 73 | 2.9 × 10-16 | 6.1 × 10-13 | 3.1 |
| GO:0003712 - transcription cofactor activity | Muscle | 23 | 3.2 × 10-9 | 4.9 × 10-6 | 4.9 |
| | | | | | |
| GO:0007267 - cell-cell signaling | Blood | 56 | 8.9 × 10-28 | 1.6 × 10-24 | 6.5 |
| GO:0007267 - cell-cell signaling | Brain | 64 | 4.3 × 10-21 | 7.8 × 10-18 | 4.2 |
| GO:0030182 - neuron differentiation | Kidney | 117 | 4.5 × 10-37 | 8.2 × 10-34 | 4.1 |
| GO:0016563 - transcription activator activity | Muscle | 29 | 5.0 × 10-10 | 7.5 × 10-7 | 4.2 |
| | | | | | |
| GO:0005886 - plasma membrane | Blood | 169 | 1.2 × 10-23 | 1.6 × 10-20 | 2.1 |
| GO:0031226 - intrinsic to plasma membrane | Brain | 119 | 1.7 × 10-36 | 2.5 × 10-33 | 3.8 |
| GO:0031226 - intrinsic to plasma membrane | Kidney | 209 | 1.3 × 10-60 | 1.9 × 10-57 | 3.7 |
| GO:0006350 - transcription | Muscle | 102 | 1.5 × 10-18 | 2.6 × 10-15 | 2.6 |
| | | | | | |
| GO:0006952 - defense response | Kidney | 58 | 5.8 × 10-30 | 1.0 × 10-26 | 6.8 |
| GO:0005887 - integral to plasma membrane | Kidney | 68 | 2.0 × 10-22 | 2.7 × 10-19 | 4.0 |
| GO:0006954 - inflammatory response | Kidney | 30 | 7.3 × 10-15 | 1.3 × 10-11 | 6.5 |
| GO:0009611 - response to wounding | Kidney | 39 | 2.2 × 10-14 | 3.8 × 10-11 | 4.6 |
| GO:0005886 - plasma membrane | Kidney | 138 | 9.1 × 10-14 | 1.2 × 10-10 | 1.8 |
| GO:0006936 - muscle contraction | Muscle | 15 | 1.5 × 10-11 | 2.5 × 10-8 | 13.0 |
| GO:0003012 - muscle system process | Muscle | 15 | 7.6 × 10-11 | 1.3 × 10-7 | 11.5 |
| GO:0006941 - striated muscle contraction | Muscle | 10 | 1.3 × 10-9 | 2.2x10-6 | 21.3 |
| GO:0015629 - actin cytoskeleton | Muscle | 15 | 3.6 × 10-6 | 4.7 × 10-3 | 4.8 |
| GO:0003009 - skeletal muscle contraction | Muscle | 5 | 5.0 × 10-6 | 8.3 × 10-3 | 44.3 |
| | | | | | |
| GO:0006955 - immune response | Kidney | 66 | 2.6 × 10-32 | 4.5 × 10-29 | 6.3 |
| GO:0031226 - intrinsic to plasma membrane | Kidney | 69 | 2.1 × 10-22 | 2.7 × 10-19 | 4.0 |
| GO:0005576 - extracellular region | Kidney | 105 | 1.8 × 10-15 | 2.3 × 10-12 | 2.2 |
| GO:0044459 - plasma membrane part | Kidney | 95 | 7.5 × 10-13 | 9.9 × 10-10 | 2.1 |
| GO:0002684 - positive regulation of immune | | | | | |
| system process | Kidney | 24 | 1.3 × 10-10 | 2.3 × 10-7 | 5.5 |
aDAVID v6.7 was used with all genes represented on the Methylation27 beadchip as background and gene lists associated for each tissue according to minimum age-associated P-value and positive or negative ageCGs. Enrichment tests were done independently for each tissue. Complete results are shown in supplemental data. All results shown are below q < 0.05 as generated by DAVID analysis [27,28].
bResults were first sorted by shared GO terms among tissues according to whether they overlapped among all four tissues (four-way), among three tissues (three-way), between two tissues (two-way), or unique in only one tissue. GO terms were then sorted by tissue and lowest q-values. The top GO term is shown for each tissue using this sorting scheme.
cThe top five genes affiliated with unique negative ageCGs in each tissue shown here do not include genes from brain because results did not meet q < 0.05for blood tissue see below.
dAll genes affiliated with negative ageCGs in blood were shared with kidney. Results are only shown here for kidney tissue.
AgeCGs and nonageCGs affiliated with gene expression within tissues classified by CpG context
| | | | | | |
| All | 271 (46.2) | 315 (53.8) | 4610 (78.4) | 1270 (21.6) | <2.2 × 10-16 * |
| Island only | 121 (36.1) | 214 (63.9) | 2251 (89.0) | 277 (11.0) | <2.2 × 10-16 * |
| Shore only | 101 (72.7) | 38 (27.3) | 1610 (83.5) | 317 (16.5) | 1.5 × 10-3 * |
| Other only | 49 (43.8) | 63 (56.2) | 749 (52.6) | 676 (47.4) | 0.09 |
| | | | | | |
| All | 591 (78.8) | 159 (21.2) | 4404 (89.3) | 528 (10.7) | 3.5 × 10-16 * |
| Island only | 328 (79.4) | 85 (20.6) | 2243 (97.0) | 70 (3.0) | <2.2 × 10-16 * |
| Shore only | 184 (85.6) | 31 (14.4) | 1564 (95.0) | 82 (5.0) | 1.2 × 10-7 * |
| Other only | 79 (64.8) | 43 (35.2) | 597 (61.4) | 376 (38.6) | 0.53 |
| | | | | | |
| All | 1209 (77.4) | 354 (22.6) | 4046 (89.9) | 456 (10.1) | <2.2 × 10-16 * |
| Island only | 402 (71.2) | 163 (28.8) | 2089 (97.5) | 54 (2.5) | <2.2 × 10-16 * |
| Shore only | 440 (85.8) | 73 (14.2) | 1362 (95.0) | 71 (5.0) | 1.1 × 10-11 * |
| Other onlye | 367 (75.7) | 118 (24.3) | 595 (64.3) | 331(35.7) | 1.6 × 10-5 * |
| | | | | | |
| Allf | 515 (77.2) | 152 (22.8) | 2784 (71.8) | 1095 (28.2) | 4.2 × 10-3 |
| Island only | 258 (78.4) | 71 (21.6) | 1262 (87.3) | 184 (12.7) | 5.2 × 10-5 * |
| Shore only | 142 (86.1) | 23 (13.9) | 1065 (82.0) | 233 (18.0) | 0.24 |
| Other only | 115 (66.5) | 58 (33.5) | 457 (40.3) | 678 (59.7) | 1.6 × 10-10 * |
aExpressed genes, FPKM > 0.25; non-expressed genes, FPKM < 0.05. Parentheses indicate percentage of total in each CpG context category.
b,cGenes in proximity to an ageCG or non-ageCG according to the smallest age-associated P-value for representative genes in each tissue.
dResulting P-values from Pearson’s Chi-squared tests between numbers of ageCGs and non-ageCGs within each classification.
eAgeCGs/genes found within CGOs from kidney showed a significantly greater number of expressed genes compared to non-ageCGs in kidney.
fMuscle was the only tissue that showed a greater number of total ageCGs/genes expressed compared to non-ageCGs/genes regardless of CpG contextthis same effect was observed within the CGO category.
*Significant P-values meet Bonferroni correction for multiple testing.
Number of unique and shared ageCGs/genes affiliated with genes expressed within tissues
| 13 (65.0) | 7 (35.0) | 8 (22.9) | 27 (77.1) | 0.003 * | |
| 16 (72.7) | 6 (27.3) | 27 (75.0) | 9 (25.0) | 0.766 | |
| 82 (78.8) | 22 (21.2) | 17 (56.7) | 13 (43.3) | 0.019 | |
| 84 (88.4) | 11 (11.6) | 11 (42.3) | 15 (57.7) | 3.40 × 10-6 * | |
aExpressed genes, FPKM > 0.25; non-expressed genes, FPKM < 0.05. Parentheses indicate percentage of total in each CpG context category.
bUnique ageCGs/genes had q < 0.05 from linear regression results in one tissue and q > 0.5 for the same affiliated gene in the other three tissues.
cShared ageCGs/genes had q < 0.05 in all four tissues.
dResulting P-values from Fisher’s exact tests between the number of unique and shared, expressed or non-expressed ageCGs/genes within tissues.
*Significant P-values meet Bonferroni correction for multiple testing.
Figure 4Jointly learned tissue-specific chromatin states across four human tissues and functional enrichments within positive and negative ageCG positions. Ten input chromatin states using Roadmap Epigenome ChIP-seq data for six histone modifications across four human tissues were used with ChromHMM software. (A) Heatmap/table shows learned emission parameters based on genome-wide combinations of histone marks. Values indicate observed frequencies of histone modifications found at genomic positions corresponding with chromatin states. (B) Transitional parameter heatmap/table shows probabilities of transitions between states (multiplied by 100). Rows show the 'from' chromatin state and columns show the 'to' chromatin state, that is, a 17% probability that chromatin state 7 transitioned into state 8. (C) Heatmap/table depicts percentage of the genome for each chromatin state (topmost row) and relative fold functional enrichments of genome category (that is, vista enhancers, lamin B1 laminB1lads, CpGs within CGIs, CGSs, CGOs, positive (+) and negative (-) ageCGs and non-ageCGs). Enrichments for chromatin states underlying ChIP-seq CTCF binding sites were determined using ENCODE data for CD14+ and CD20+ cells (merged peaks blood), kidney tissue, and myotubes (brain data not available). Overlap enrichments were determined separately for each tissue using tissue-specific segmentation files generated from the jointly learned model. Values across rows indicate relative fold enrichment, and blue color scale is based on subtraction of the minimum value in the row divided by the maximum row value for each tissue separately (vertical black lines divide table enrichments per tissue). (D) Neighborhood enrichments for RefSeq transcriptional start site annotations (TSS) within chromatin states determined using default 0-based anchor coordinates for each start site position. Fold enrichment values and color scale are according to rows. In all panels, the lower axis shows chromatin state colored to match chromatin state descriptions (1 to 10).
Figure 5Validation of ageCGs by targeted capture and bisulfite sequencing of genomic regions encompassing ageCG sites. (A) Scatterplots of percentage methylation by bisulfite sequencing (Bis-seq) versus Methylation27 β-score and correlation of methylation values between the two methods across 19 kidney samples used for validation. (B) A representative Bland-Altman plot for comparison of Bis-seq and Methylation27 methylation values. Points depict the average percentage methylation between both methods plotted against the differences in methylation between the methods. Dotted lines show limits of agreement (average difference ± 1.96 standard deviation of the difference). (C, D) Comparison of methylation delta values (median percentage methylation of young minus old samples) at CpGs covered by Bis-seq (top panels) and Methylation27 arrays (middle panels). Red points represent ageCGs, and delta values shown for Bis-seq are only for the 9 youngest and 10 oldest samples. False discovery rate (q) values indicate significance level of a widespread age effect by linear mixed model results with Bis-seq data at these target regions. The DKK1 target just missed the significance threshold (q < 0.05), and the RLN1 target demonstrates an example region that contained abrupt changes in direction of delta values among neighboring CpGs. Bottom panels depict labeled gene regions (blue boxes, exons blue lines, introns), CpG islands (green boxes), and fetal kidney chromatin states (colors correspond with definitions in Figure 4). Greater details and examples of all Bis-seq targets are available in Additional files 7 and 24.
Descriptive features and enrichments of differentially methylated sites with age across human blood, brain, kidney, and skeletal muscle tissues
| Within CGIs | Within CGSs, CGOs |
| Generally hypomethylated | Generally hypermethylated |
| Smaller relative slope magnitude | Larger relative slope magnitude |
| Greater enrichment in H3K27Me3 | Less enrichment in H3K27Me3 |
| More shared sites across tissues | More unique sites across tissues |
| Genes with lower relative FPKM | Genes with higher relative FPKM |
| Near development-related genes | Near tissue-specific regulated genes |
| Generally further from CTCF sites | Generally closer to CTCF sites |
| Enriched within LADs | Not enriched in LADs |